Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05041907 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Study acronym: PLATCOV
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Oct 23, 2024, no change to tracked fieldsv14-v16
  2. Enrollment target: 3000 to 3800v13 Show 4 more changesShow less
    • Study sites: 6 to 7
    • Interventions: Ensitrelvir (Drug), Favipiravir (Drug), Fluoxetine (Drug), Hydroxychloroquine (Drug), Ivermectin (Drug), Molnupiravir (Drug), Molnupiravir… to Atilotrelvir/ritonavir (Drug), Ensitrelvir (Drug), Favipiravir (Drug), Fluoxetine (Drug), Hydroxychloroquine (Drug), Ivermectin (Drug)…
    • Study description expanded, about 88 words
    • Study arms: 14 to 19
  3. Study description shortened, about 30 words
    • Site details revised at 1 of 6 sites
    v12
  4. Study description expanded, about 18 wordsv11
  5. Enrollment target: 1500 to 3000v10 Show 8 more changesShow less
    • Primary and study completion dates: Aug 2024 to Jan 2027
    • Primary endpoints: 3 to 2
    • Study sites: 5 to 6
    • Interventions: Ensitrelvir (Drug), Favipiravir (Drug), Fluoxetine (Drug), Ivermectin (Drug), Molnupiravir (Drug), Molnupiravir and nirmatrelvir/ritonavir… to Ensitrelvir (Drug), Favipiravir (Drug), Fluoxetine (Drug), Hydroxychloroquine (Drug), Ivermectin (Drug), Molnupiravir (Drug), Molnupiravir…
    • Eligibility criteria revised
    • Secondary endpoints: 3 to 4
    • Study description shortened, about 35 words
    • Study arms: 13 to 14
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Study sites: 4 to 5
    • Interventions: Favipiravir (Drug), Fluoxetine (Drug), Ivermectin (Drug), Molnupiravir (Drug), Monoclonal antibodies (Drug), Nirmatrelvir/ritonavir (e.g… to Ensitrelvir (Drug), Favipiravir (Drug), Fluoxetine (Drug), Ivermectin (Drug), Molnupiravir (Drug), Molnupiravir and nirmatrelvir/ritonavir…
    • Study description expanded, about 36 words
    • Study arms: 9 to 13
    v8
  3. Enrollment target: 750 to 1500v7 Show 8 more changesShow less
    • Primary and study completion dates: Aug 2023 to Aug 2024
    • Primary endpoints revised (3)
    • Interventions: Favipiravir (Drug), Ivermectin (Drug), Monoclonal antibodies (Drug), No treatment (Other), Remdesivir (Drug) to Favipiravir (Drug), Fluoxetine (Drug), Ivermectin (Drug), Molnupiravir (Drug), Monoclonal antibodies (Drug), Nirmatrelvir/ritonavir (e.g…
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints revised (3)
    • Study description expanded, about 112 words
    • Site details revised at 2 of 4 sites
    • Study arms: 5 to 9
  4. Site details revised at 1 of 4 sitesv6
  5. Re-verified, no change to tracked fieldsv5
  6. Study sites: 3 to 4v4
  7. Study sites: 1 to 3v3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2021 to Sep 30, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity. In this randomized open label, controlled, group sequential adaptive platform trial, we will assess the performance of three distinct types of intervention relative to control (no treatment): A: Small molecule drugs; B: Monoclonal antibodies; C: Dose finding for the constituent parts of nirmatrelvir/ritonavir PLATCOV study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.
Trial Details
NCT Number NCT05041907
Lead Sponsor University of Oxford
Conditions
(from sponsor)		 COVID-19
Related terms COVID-19
Enrollment 3,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov